معرفی
Sonia Lain is a Professor at Karolinska Institutet's Department of Microbiology, Tumor and Cell Biology. She leads the 'Discovery and Elucidation of the mechanisms of Action of Tumour Selective Compunds' research group, part of the Division of Tumor Biology. Her work focuses on identifying molecules with therapeutic potential for cancer, particularly targeting DHODH (dihydroorotate dehydrogenase) inhibitors and p53 pathway activation. She holds a Docent degree from Karolinska Institutet (2012) and has been a professor since 2015. Her research integrates biochemistry, cell biology, and molecular oncology to develop novel cancer therapies.
Research interests include tumor-selective compounds, pyrimidine metabolism, and the p53 signaling pathway. Her group investigates how DHODH inhibitors disrupt cancer cell proliferation while sparing normal cells. Key projects involve modulating nucleotide imbalance in tumors and understanding mechanisms of drug resistance.
Publications highlight advancements in DHODH inhibitor mechanisms, metabolic effects of these compounds, and p53 activation strategies. The lab's work has been featured in journals like Nature Communications and Cell Chemical Biology. Collaborations with institutions like KTH and the University of Oxford underscore interdisciplinary approaches to drug discovery.
No specific grants or awards are listed, but her group's research is supported by donations. She advises on lab activities but no formal student names are provided. The lab's future work includes optimizing DHODH inhibitors for clinical translation and exploring combination therapies.